Preclinical combination therapies involving ATRi were investigated with temozolomide in O6-methylguanine-DNA methyltransferase (MGMT)-deficient glioma cells [21] as well as with the oncolytic CAN-2409/Ganciclovir system [22]. Here, MGMT is linked to central nervous system cancer.